GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control

Greenhaven Road Capital, an investment management company, announced its latest Q2 2026 investor letter, detailing their latest strategies and holdings. The fund achieved a net return of approximately 11% during the second quarter, showing progress from the first quarter. In order to maintain a strong portfolio, Greenhaven Road Capital is implementing a lower concentration strategy with increased investments that have near-term catalysts.

They also adopt a proactive approach to profit-taking and continue to prioritize owning strong businesses, as well as conducting research that challenges consensus views. Many of their current investments require patience, but some, like AnaptysBio, Inc. (NASDAQ:ANAB), may not need as much time to compound value. AnaptysBio is a clinical-stage biotechnology company that focuses on immunology therapeutics for autoimmune and inflammatory diseases.

The company was acquired by Tesaro in 2014 and later acquired by GSK in 2021. AnaptysBio's cancer drug Jemperli has generated over $1 billion in revenue for GSK, marking a significant milestone in the company's growth.